Bluebird Bio Stock News

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for elivaldogene autotemcel (eli-cel, Lenti-D®), the companys gene therapy for cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age. Eli-cel is an investigational one-time gene therapy, custom-designed to treat the underlying cause of this irreversible neurodegenerativ

Novo Nordisk A/S with ticker code (NVO) have now 2 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 118.23 and 114.45 calculating the average target price we see 116.34. With the stocks previous close at 116.46 this is indicating there is a potential downside of -.1%. The 50 day MA is 109.09 while the 200 day moving average is 91.2. The company has a market capitalisation of $266,893m. Visit the company website at: https://www.novonordisk.com [stock_market_widget type="chart" symbol="NVO" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.

Bluebird (BLUE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates

This company has made quite a lot of noise recently.

Bluebird (BLUE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates

This company has made quite a lot of noise recently.

In todays recent session, 1.78 million shares of the bluebird bio Inc. (NASDAQ:BLUE) have been traded, and its beta is 1.58. Most recently the companys share price was $9.40, and it changed around $0.44 or 4.97% from the last close, which brings the market valuation of the company to $671.01M. BLUE at last check was bluebird bio Inc. (NASDAQ: BLUE) Stock: Can It Go Higher? Read More »

The trading price of bluebird bio Inc. (NASDAQ:BLUE) closed lower on Friday, December 10, closing at $8.96, -4.48% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

(RTTNews) - The following are some of the stocks making big moves in Monday''s pre-market trading (as of 07.10 A.M. ET). In the Green Arena Pharmaceuticals, Inc. (ARNA) is up over 97% at $98.63 Foghorn Therapeutics Inc. (FHTX) is up over 35% at $16.27 Petros Pharmaceuticals, Inc. (PTPI) is up over 31% at $3.55 bluebird bio, Inc.

bluebird bio Inc. (BLUE) shares were rising 14.96% to trade at $10.30 in pre-market at last check. BLUE stock lost -4.48% to close weekend session at $8.96. Volume of BLUE stock remained 1.28 million shares, which was slightly lower than the average daily volume of 1.64 million shares within the past 50 days. BLUE shares … What Is Driving The bluebird (BLUE) Stock Up 15% In Premarket Session? Read More »

The stock price of bluebird bio Inc (NASDAQ: BLUE) increased by over 3% during intraday trading today. This is why it happened.

Bluebird bio Inc (NASDAQ: BLUE) announced updated results from its Phase 1/2 HGB-206 study of lovotibeglogene autotemcel (lovo-cel; formerly LentiGlobin for SCD, bb1111) gene therapy for sickle cel

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (NASDAQ: BLUE) today announced updated results from its Phase 1/2 HGB-206 study of lovotibeglogene autotemcel (lovo-cel; formerly LentiGlobin® for SCD, bb1111) gene therapy for sickle cell disease, including further analyses from its pivotal cohort, HGB-206 Group C, following enhancements to the manufacturing protocols and treatment process. In addition to continued complete resolution of severe vaso-occlusive events (VOEs), patients in Grou

Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple conference presentations